Chen G, McQuade JL, Panka DJ, et al. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016;2(8):1056-64. doi:10.1001/jamaoncol.2016.0509
Nagaraja AK, Bass AJ. Hitting the Target in BRAF-Mutant Colorectal Cancer. J Clin Oncol. 2015;33(34):3990-2. doi:10.1200/JCO.2015.63.7793
Gupta S, Artomov M, Goggins W, Daly M, Tsao H. Gender Disparity and Mutation Burden in Metastatic Melanoma. J Natl Cancer Inst. 2015;107(11). doi:10.1093/jnci/djv221
Kang HB, Fan J, Lin R, et al. Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell. 2015;59(3):345-58. doi:10.1016/j.molcel.2015.05.037
Rameseder J, Krismer K, Dayma Y, et al. A Multivariate Computational Method to Analyze High-Content RNAi Screening Data. J Biomol Screen. 2015;20(8):985-97. doi:10.1177/1087057115583037
Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-62. doi:10.1038/nature04304
Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep. 2015;17(4):15. doi:10.1007/s11912-015-0438-0
Konermann S, Brigham MD, Trevino AE, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517(7536):583-8. doi:10.1038/nature14136
Sadow PM, Priolo C, Nanni S, et al. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. J Natl Cancer Inst. 2014;106(8). doi:10.1093/jnci/dju182
Pugh TJ, Yu W, Yang J, et al. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014;33(45):5295-302. doi:10.1038/onc.2014.150